Sunshine Biopharma Launches Generic Pravastatin in Canada Through Nora Pharma Subsidiary
Key Insights
Sunshine Biopharma (search)'s Canadian subsidiary Nora Pharma (search) has launched generic Pravastatin, a cholesterol-lowering statin medication available in 10 mg, 20 mg, and 40 mg strengths.
The drug is a generic version of Pravachol® that works by lowering LDL cholesterol (search) and increasing HDL cholesterol (search) to prevent cardiovascular conditions.
IQVIA estimates the Canadian cholesterol-lowering drugs market will reach $582 million by 2025 and expand at 8% CAGR to $1.07 billion by 2033.
Sunshine Biopharma (search) Inc. (NASDAQ:SBFM) announced that its wholly owned Canadian subsidiary, Nora Pharma (search) Inc., has launched Pravastatin, a generic prescription drug in the therapeutic class of Lipid Metabolism Regulators. The launch expands the company's growing portfolio of generic medications in the Canadian market.
Product Details and Mechanism
Pravastatin is a generic version of Pravachol® that functions as a statin medication by lowering bad cholesterol (LDL) and increasing good cholesterol (HDL) in the blood. This mechanism helps prevent heart attacks, strokes, and other serious cardiovascular conditions. Nora Pharma (search)'s Pravastatin is available in three strengths: 10 mg, 20 mg, and 40 mg, packaged in bottles of 100 tablets.
Market Opportunity and Growth Projections
According to IQVIA data, the Canadian market for cholesterol-lowering drugs is estimated to reach USD $582 million by the end of 2025. The market research firm projects significant expansion, estimating the cholesterol-lowering drugs market in Canada will grow at a compound annual growth rate (CAGR) of 8% per year, reaching USD $1.07 billion by 2033.
The global market presents an even larger opportunity, with Biospace projecting the lipid-lowering drugs market size to surpass USD $46.58 billion by 2033, highlighting the substantial commercial potential for cholesterol management therapies.
Company Portfolio and Pipeline
"We are excited to introduce Pravastatin to the market," said Steve Slilaty, CEO of Sunshine Biopharma (search). "This launch reinforces our dedication to improving patient outcomes through innovative therapies that address critical health needs."
Sunshine Biopharma (search) currently maintains a robust presence in the Canadian generic drug market with 74 generic prescription drugs already available. The company has scheduled more than 12 additional drug launches for 2026, indicating continued expansion of its commercial portfolio.
Research and Development Activities
Beyond its generic drug business, Sunshine Biopharma (search) is conducting a proprietary drug development program focused on two key areas. The pipeline includes K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer (search) treatment, and PLpro protease inhibitor (search), a small molecule designed for treatment of SARS Coronavirus infections (search).
The Pravastatin launch addresses cardiovascular disease (search), which remains a top global health challenge, as Nora Pharma (search) commits to providing effective and accessible treatment options for patients requiring cholesterol management therapy.